Trials / Completed
CompletedNCT03888755
A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Participants
An Open-Label Study of Icatibant in Japanese Subjects With Acute Attacks of Hereditary Angioedema.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Shire · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the efficacy, pharmacokinetics (PK), and safety of icatibant for the treatment of acute attacks in Japanese participants with type I or type II hereditary angioedema (HAE).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Icatibant | Participants will receive icatibant 30 mg SC injection in the abdominal area. |
Timeline
- Start date
- 2015-03-18
- Primary completion
- 2016-02-12
- Completion
- 2016-02-12
- First posted
- 2019-03-25
- Last updated
- 2021-06-03
- Results posted
- 2019-08-08
Locations
8 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT03888755. Inclusion in this directory is not an endorsement.